SG/CALL/ABBVIE/200/0.1/20.06.25 Stock

Warrant

DE000SU6E3B6

Real-time Boerse Frankfurt Warrants 02:45:32 2024-05-21 EDT
0.4 EUR -2.44% Intraday chart for SG/CALL/ABBVIE/200/0.1/20.06.25
Current month-10.87%
1 month-37.88%
Date Price Change
24-05-21 0.4 -2.44%
24-05-20 0.41 -8.89%
24-05-17 0.45 +9.76%
24-05-16 0.41 0.00%
24-05-15 0.41 +10.81%

Real-time Boerse Frankfurt Warrants

Last update May 21, 2024 at 02:45 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ABBVIE INC.
IssuerLogo Issuer Société Générale Société Générale
WKN SU6E3B
ISINDE000SU6E3B6
Date issued 2023-12-29
Strike 200 $
Maturity 2025-06-20 (396 Days)
Parity 10 : 1
Emission price 0.34
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.21
Lowest since issue 0.31
Spread 0.05
Spread %11.11%

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
-
More about the company

Ratings for AbbVie Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: AbbVie Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
164.6 USD
Average target price
182.3 USD
Spread / Average Target
+10.76%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW